APOBEC2抗体;APOBEC2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of K562 cells using PSG1 mouse mAb (green) and negative control (red).    

  
  

APOBEC2 (apolipoprotein B mRNA-editing enzyme catalytic subunit 2) is a member of the APOBEC protein family, which consists of cytidine deaminases involved in RNA/DNA editing and innate immunity. Unlike other APOBEC members (e.g., APOBEC3G) known for antiviral roles, APOBEC2 lacks direct nucleic acid-editing activity in humans and displays distinct physiological functions. It is primarily expressed in skeletal muscle, heart, and liver tissues, suggesting tissue-specific roles in development, metabolism, or cellular homeostasis. Structural studies reveal APOBEC2 forms homodimers and may regulate lipid metabolism or muscle differentiation through protein-protein interactions rather than enzymatic editing.

Antibodies targeting APOBEC2 are critical research tools for elucidating its biological functions. They enable detection of endogenous APOBEC2 expression via Western blotting, immunohistochemistry, or immunofluorescence, aiding spatial-temporal localization studies in tissues. Some antibodies also support investigations into APOBEC2’s interaction partners and post-translational modifications. Research links APOBEC2 to metabolic disorders, muscular dystrophies, and cancer progression, though its exact mechanisms remain unclear. Commercial APOBEC2 antibodies are typically raised against conserved epitopes in humans/mice, validated for specificity using knockout controls. Challenges include limited commercial availability and cross-reactivity risks with homologous APOBEC members. Ongoing studies using these antibodies aim to clarify APOBEC2’s role in development and disease, potentially informing therapeutic strategies.